Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhoodJacques J. M. van Dongen, Claus R. Bartram, Taku Seriu et al.|The Lancet|1998Cited by 964
Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997–2004)Anna Berg, Willem A. Kamps, Henk van den Berg et al.|The Lancet Oncology|2009Cited by 250
High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group.A Van der Does-Van der Berg, K. Hählen, Willem A. Kamps et al.|Journal of Clinical Oncology|1996Cited by 208
Long-Term Results of a Randomized Trial on Extended Use of High Dose <scp>l</scp>-Asparaginase for Standard Risk Childhood Acute Lymphoblastic LeukemiaAndrea Pession, Maurizio Aricò, Maria Grazia Valsecchi et al.|Journal of Clinical Oncology|2005Cited by 202
Patient Stratification Based on Prednisolone-Vincristine-Asparaginase Resistance Profiles in Children With Acute Lymphoblastic LeukemiaMonique L. den Boer, Gritta Janka‐Schaub, D. Harms et al.|Journal of Clinical Oncology|2003Cited by 188